Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer
Open Access
- 12 December 2017
- journal article
- research article
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 8 (2) , 310-314
Abstract
A useful candidate for small‑cell lung cancer (SCLC) therapy is immune checkpoint blockade therapy targeting programmed death‑1 (PD‑1) and its ligand, PD‑L1. Furthermore, rovalpituzumab tesirine (Rova‑T), a delta‑like protein 3 (DLL3)‑targeted antibody‑drug conjugate, and enhancer of zeste homologue 2 (EZH2) inhibitor are expected to be the first targeted therapy for SCLC. The aim of the present study was to evaluate PD‑L1, DLL3 and EZH2 expression in SCLCs to find a candidate responder to those therapies. Immunohistochemical (IHC) staining for PD‑L1, DLL3 and EZH2 was performed in 20 patients with SCLC and the clinicopathological characteristics and IHC staining intensity were compared. It was demonstrated that 1/20 patients (5.0%) exhibited positive PD‑L1 expression in the metastatic lesions, as well as in the primary lung tumor. DLL3 was highly expressed in 14/20 patients (70%) and EZH2 was positive in 17/20 patients (85%). None of these cases exhibited any correlation with age, sex, smoking, stage or treatment, whereas IHC staining was able to identify candidate responders to anti‑PD‑L1/PD‑1 immunotherapy, Rova‑T therapy, or EZH2 inhibitor therapy.Keywords
This publication has 21 references indexed in Scilit:
- Unravelling the biology of SCLC: implications for therapyNature Reviews Clinical Oncology, 2017
- Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapySurgery Today, 2017
- Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 AxisCancer Cell, 2017
- Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 studyThe Lancet Oncology, 2017
- Comprehensive genomic profiles of small cell lung cancerNature, 2015
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature, 2014
- Genome‐wide identification of genes with amplification and/or fusion in small cell lung cancerGenes, Chromosomes and Cancer, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Regulation of Tumor Angiogenesis by EZH2Cancer Cell, 2010